In contrast to PERCIST 1.0, RECIST 1.1 was based on CT anatomical imaging data, when there are no target lesions, the partial response of the tumor cannot be differentiated from stable or non-progression, Due to the widespread bone metastasis in mCRPC, PERCIST 1.0 based on 68Ga-PSMA PET/CT can evaluate the molecular biological changes of tumors through molecular imaging, which can more sensitively and accurately reflect the therapeutic effect of tumors in early treatment. This evidence concerns the gene FOLH1 and neoplasm.